Opendata, web and dolomites

theEoE

A novel drug candidate for the treatment of Eosinophilic Esophagitis - an innovative solution for a significant unmet medical need

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 theEoE project word cloud

Explore the words cloud of the theEoE project. It provides you a very rough idea of what is the project "theEoE" about.

persistent    offers    compounds    foods    esophagitis    wellbeing    proprietary    lower    revenue    cellular    accumulate    fly    injury    physicians    risk    theeoe    remodeling    eosinophilic    regurgitation    therapy    series    ip    white    difficulty    local    people    revolutionary    payers    occurs    smarter    cells    progression    applies    generating    cure    causing    fits    uncontrolled    blood    reduces    investing    embryo    perfectly    modulating    necessarily    esophagus    europe2020    diseases    health    patients    modifies    possibly    environmental    company    approved    inflammation    indications    time    drug    healthier    thanks    benefit    sustainable    inflammatory    disease    epithelial    allergens    elicited    modulation    complications    promotion    eoe    tissue    persists    manufacturing    nausea    technologies    decision    first    thelial    line    prioritized    barriers    polarity    thelitetm    discovery    platform    swallowing    cell    bioavailability    pain    points    clinical    toxicology    pathologies    innovation    vomiting    fewer    spending    efficacy    eosinophils    candidate    28    integrity    patented    topical    treatment    symptoms   

Project "theEoE" data sheet

The following table provides information about the project.

Coordinator
THELIAL TECHNOLOGIES SA 

Organization address
address: PARQUE TECNOLOGICO DE CANTANHEDE, NUCLEO 4, LOTE 3
city: CANTANHEDE
postcode: 3060197
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Portugal [PT]
 Project website http://www.thelial.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-12-01   to  2017-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    THELIAL TECHNOLOGIES SA PT (CANTANHEDE) coordinator 50˙000.00

Map

 Project objective

Thelial Technologies, S.A. is a revenue generating drug discovery company that applies its unique, proprietary fly embryo-based technology to find new candidate compounds for the treatment of diseases that can be addressed by cell polarity modulation. By modulating cell polarity it is possible to specifically target a series of indications, where reduced integrity of epithelial cellular barriers is a key to pathologies. Using Thelial’s patented discovery platform theLiTETM the company has identified 28 candidate compounds, of which one – theEoE has been prioritized for further development based on toxicology, efficacy, bioavailability, IP and manufacturing decision points. theEoE will be the first approved product for treatment of Eosinophilic Esophagitis (EoE). EoE is an inflammatory disease of the esophagus elicited by foods and possibly environmental allergens. It occurs when a type of white blood cells, eosinophils, accumulate in the esophagus and persists, causing local injury and inflammation. Currently, there are no specific cure for the EoE, causing patients’ reduced wellbeing due to uncontrolled and persistent symptoms (e.g. high difficulty in swallowing, pain, nausea, regurgitation, and vomiting). Thelial offers a targeted topical treatment that reduces the clinical symptoms, modifies disease progression through tissue remodeling, and increases the duration of treatment response. These features will allow physicians, patients and payers to benefit from a revolutionary new treatment with fewer side-effects, and lower risk of health complications thanks to a better management of the disease over time. By promoting a first in line targeted therapy for EoE, Thelial’s innovation project perfectly fits the “Europe2020 challenges – for a healthier EU” 1) spending smarter but not necessarily more in sustainable health systems and 2) investing in people’s health, particularly through health-promotion programmes.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "THEEOE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "THEEOE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More